YTYudai Tamura

Yudai Tamura

*This is an algorithmically generated author record based on publicly available information.

Yudai Tamura has a total of 144 co-authors. Here are the top co-authors by number of shared publications:

  • Yuichi Tamura

    Pulmonary Hypertension Center, International University of Health and Welfare Mita Hospital

    4 shared publications
  • Tadashi Sawamura

    Department of Cardiology and Intensive Care Unit, Saiseikai Kumamoto Hospital, 5-3-1 Chikami, Minami-ku, Kumamoto City, Kumamoto 861-4193, Japan

    3 shared publications
  • Tomohiro Sakamoto

    Department of Cardiology and Intensive Care Unit, Saiseikai Kumamoto Hospital, 5-3-1 Chikami, Minami-ku, Kumamoto City, Kumamoto 861-4193, Japan

    3 shared publications
  • Eiji Taguchi

    Department of Cardiology and Intensive Care Unit, Saiseikai Kumamoto Hospital, 5-3-1 Chikami, Minami-ku, Kumamoto City, Kumamoto 861-4193, Japan

    2 shared publications
  • Hiroaki Kawano

    Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences

    2 shared publications
  • Koichi Nakao

    Department of Cardiology and Intensive Care Unit, Saiseikai Kumamoto Hospital, 5-3-1 Chikami, Minami-ku, Kumamoto City, Kumamoto 861-4193, Japan

    2 shared publications

Latest Publications

  • Open Access

    Excimer Laser for Calcified Nodule-Driven Early Stent Failure

    by Yasunori Inoguchi, Ryo Nishikawa, Yohei Yakuta, Taiji Yoshida, Yudai Tamura

  • Open Access

    Asymptomatic and symptomatic cardiac toxicity associated with immune checkpoint inhibitors: insights from a Japanese registry

    by Yudai Tamura, Yuichi Tamura, Hiroshi Ohtsu, Shiro Nakamori, Kazuaki Maruyama, Nao Muraoka, Masaaki Shoji, Kazuko Tajiri, Hirofumi Tomita, Yoshitaka Iso, et al.

    Aims: Immune checkpoint inhibitors (ICIs) are a cornerstone of cancer therapy; however, immune-related adverse events, including myocarditis, pose significant challenges. Furthermore, limited data exist on the pathology of mild or asymptomatic cases. This study aimed to characterize the clinical, biomarker, and pathological features of ICI-associated cardiac toxicity, comparing symptomatic and asymptomatic cases within a Japanese multicentre registry. Methods and results: A nationwide, retrospective registry collected data from 90 patients across 23 hospitals between 2020 and 2022. Patients were classified according to the American Society of Clinical Oncology Clinical Practice Guidelines: Grade 1 (asymptomatic) and Grades 2–4 (symptomatic). Endomyocardial biopsy was performed in 24 patients (n = 19 symptomatic, n = 5 asymptomatic). Among the enrolled patients (mean age: 68 years; 76.7% male), 41.1% were classified as Grade 1, whereas 58.9% were symptomatic (Grades 2–4). Symptomatic cases exhibited significantly higher troponin I and creatine kinase levels at onset. Pathological analysis revealed more extensive lymphocytic infiltration (CD3+ T cells) in symptomatic cases, particularly with higher CD8+ and CD68+ cell counts. Continuation of ICI therapy was more frequent in the asymptomatic group, and only one patient experienced recurrence. In contrast, all seven myocarditis-related deaths occurred in symptomatic patients. Conclusion: This study provides one of the largest pathological and biomarker-based comparisons of symptomatic and asymptomatic ICI-associated cardiac toxicity. Our findings suggest that asymptomatic cases may represent a distinct, less aggressive inflammatory phenotype, characterized by lower CD8+ infiltration and limited myocardial damage.


  • Open Access

    Usefulness of Longitudinal Strain to Assess Cancer Therapy-Related Cardiac Dysfunction and Immune Checkpoint Inhibitor-Induced Myocarditis

    by Yudai Tamura, Yuichi Tamura

    Longitudinal strain (LS) measured by echocardiography has been reported to be useful not only for the diagnosis and risk stratification of various cardiac diseases, but also in cardio-oncology. Most previous studies have been conducted on patients undergoing treatment with anthracyclines and human epidermal growth factor receptor 2-targeted therapies. Existing guidelines recommend that global LS (GLS) should be measured before and after the administration of cancer drugs. This recommendation is based on many reports showing that a decline in GLS is indicative of early or mild cancer therapy-related cardiac dysfunction. The main purpose of this article is to provide insight into the importance of LS in patients undergoing cancer treatment and highlight the role of LS evaluation in patients undergoing immune checkpoint inhibitor (ICI) treatment, which is being used with increasing frequency. Among cancer drug therapies, immune checkpoint inhibitors (ICIs) have an important place in cancer treatment and are used for the treatment of many types of cancer. Although the efficacy of ICIs in cancer treatment has been reported, immune-related adverse events (irAEs) have also been reported. Among these irAEs, cardiovascular complications, although rare, are recognized as important adverse events that may result in ICI treatment discontinuation. Myocarditis is one severe adverse event associated with ICIs, and it is important to standardize diagnostic and therapeutic approaches to it. Several studies have reported a relationship between LS and cardiac complications associated with ICIs which may contribute to the early diagnosis of ICI-induced cardiac complications.


  • Open Access

    Content

    by Akira Sezai, Tomoki Shimokawa, Koshiro Kanaoka, Nagaharu Fukuma, Hisakuni Sekino, Hirokazu Shiraishi, Yoko Sumita, Michikazu Nakai, Yoshitaka Iwanaga, Yutaka Furukawa, et al.

    Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.

  • Open Access

    Impact of extracorporeal CPR with transcatheter heart pump support (ECPELLA) on improvement of short-term survival and neurological outcome in patients with refractory cardiac arrest – A single-site retrospective cohort study

    by Takashi Unoki, Motoko Kamentani, Tomoko Nakayama, Yudai Tamura, Yutaka Konami, Hiroto Suzuyama, Masayuki Inoue, Megumi Yamamuro, Eiji Taguchi, Tadashi Sawamura, et al.


  • Open Access

    Predictors of hypoxemia in type-B acute aortic syndrome: a retrospective study

    by Yudai Tamura, Yuichi Tamura, Motoko Kametani, Yoshiaki Minami, Tomoko Nakayama, Daisuke Takagi, Takashi Unoki, Megumi Yamamuro, Akio Kawamura, Tomohiro Sakamoto, et al.

    Acute aortic syndrome (AAS) can be life-threatening owing to a variety of complications, and it is managed in the intensive care unit (ICU). Although Stanford type-B AAS may involve hypoxemia, its predictors are not yet clearly understood. We studied clinical factors and imaging parameters for predicting hypoxemia after the onset of type-B AAS. We retrospectively analyzed patients diagnosed with type-B AAS in our hospital between January 2012 and April 2020. We defined hypoxemia as PaO2/FiO2 ≤ 200 within 7 days after AAS onset and used logistic regression analysis to evaluate prognostic factors for hypoxemia. We analyzed 224 consecutive patients (140 males, mean age 70 ± 14 years) from a total cohort of 267 patients. Among these, 53 (23.7%) had hypoxemia. The hypoxemia group had longer ICU and hospital stays compared with the non-hypoxemia group (median 20 vs. 16 days, respectively; p = 0.039 and median 7 vs. 5 days, respectively; p < 0.001). Male sex (odds ratio [OR] 2.87; 95% confidence interval [CI] 1.24–6.63; p = 0.014), obesity (OR 2.36; 95% CI 1.13–4.97; p = 0.023), patent false lumen (OR 2.33; 95% CI 1.09–4.99; p = 0.029), and high D-dimer level (OR 1.01; 95% CI 1.00–1.02; p = 0.047) were independently associated with hypoxemia by multivariate logistic analysis. This study showed a significant difference in duration of ICU and hospital stays between patients with and without hypoxemia. Furthermore, male sex, obesity, patent false lumen, and high D-dimer level may be significantly associated with hypoxemia in patients with type-B AAS.


  • Open Access

    Inappropriate sinus tachycardia-induced cardiomyopathy with severe functional mitral regurgitation and successful treatment with ivabradine

    by Taiji Inamori, Kazuhisa Kodama, Yudai Tamura, Hideharu Okamatsu, Yukiko Sashida, Yoko Horibata, Eiji Taguchi, Koichi Nakao, Tomohiro Sakamoto


  • The first described case of late infective endocarditis after implantation of Figulla Flex Ⅱ ASD occluder

    by Yudai Tamura, Yuki Yonehara, Yoko Horibata, Hideyuki Uesugi, Tadashi Sawamura, Tomohiro Sakamoto


  • Open Access

    Platypnoea–orthodeoxia syndrome induced by short-term weight loss: a case series

    by Yudai Tamura, Tomohiro Sakamoto

    Background: Platypnoea–orthodeoxia syndrome (POS) is an uncommon condition characterized by dyspnoea and arterial desaturation in the standing or sitting position that improves in the supine position. Case summary: We report two cases of POS caused by an atrial septal defect (ASD) and a patent foramen ovale (PFO). Both cases reported a recent decrease in body weight of more than 10 kg in a short time period. Transoesophageal echocardiography (TOE) with agitated saline bubble study revealed and a large amount of contrast bubble through the ASD (Patient 1) or the PFO (Patient 2) from the right atrium to the left atrium in the sitting position. Both patients were diagnosed by the finding of positional dyspnoea and the results of TOE using agitated saline bubble contrast. Discussion: Taken together, their presentations suggest that weight loss in a short time period could be a pathogenic factor for POS.


  • Open Access

    Quick sepsis‐related organ failure assessment score as a possible predictor for in‐hospital adverse events in infective endocarditis

    by Yudai Tamura, Akihiro Nomura, Shohei Yoshida, Hayato Tada, Kenji Sakata, Kenji Iino, Hiroshi Furusho, Masayuki Takamura, Hirofumi Takemura, Masakazu Yamagishi, et al.

    Aim: Infective endocarditis (IE) can be life‐threatening because of various associated adverse events. The quick Sepsis‐related Organ Failure Assessment (qSOFA) score is a straightforward useful method for predicting in‐hospital mortality in patients with suspected infections. However, few data exist regarding the clinical impact of the qSOFA score on predicting adverse events in IE during hospitalization. We studied the usefulness of qSOFA score for predicting in‐hospital adverse events in patients with IE.Methods: We retrospectively analyzed 104 consecutive patients diagnosed with IE on the basis of modified Duke criteria. We defined in‐hospital adverse events as occurrence of any of the following events during hospitalization: death, embolism, hemorrhage, or abscess formation. The high qSOFA group was defined as those with a qSOFA score ≥2. We used Cox regression analysis to estimate the hazard ratio for high qSOFA score on in‐hospital adverse events adjusted for age, sex, and Staphylococcus aureus infection.Results: We analyzed 83 patients (57 men, mean age 61 ± 18 years) from the total cohort of 104 patients enrolled. Among these, 12 (14.5%) had high qSOFA scores. The high qSOFA group had higher in‐hospital mortality compared to the low qSOFA group (50.0% vs. 4.2%, P < 0.01). In the Cox proportional hazards model, high qSOFA was significantly associated with in‐hospital adverse events (adjusted hazard ratio, 2.29; confidence interval, 1.02–5.12; P = 0.044).Conclusion: These results showed that high qSOFA score was significantly associated with in‐hospital adverse events in IE patients, although further prospective study is necessary to confirm our results.